OVARIAN CANCER

This early-phase study tests whether adding the drug lurbinectedin to two standard chemotherapy drugs (paclitaxel and bevacizumab) can help control advanced ovarian cancer that no longer responds to platinum-based treatments. About 34 adults with this type of cancer will take par…

This early-phase trial tests whether a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, can safely shrink tumors in adults with ovarian cancer that has returned after platinum-based chemotherapy. About 48 participants will receive the cells e…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This early-phase study tests an experimental oral drug called ATX-295 in about 90 adults with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also …

This early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…

This early-phase study tests a new drug, DT2216, combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel. About 30 participan…

This early-stage trial tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The study aims to find a safe dose and see if the treatment can shrink tumors. About 18 …

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This early-stage study tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer and tumors with a specific gene change (CCNE1). The main goals are to find a safe dose and see how well the drug works. About 361 participants will…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses the patient's own T cells, which are modified in…

This study tests a new drug called SHR-A1811 in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. Participants will receive either SHR-A1811 or a standard chemotherapy chosen by their doctor. The main goa…

This study tests a new drug called mirvetuximab soravtansine, combined with either carboplatin or bevacizumab, in people with a specific type of ovarian cancer. About 320 participants will receive different doses to see which works best and is safest. The goal is to control the d…

This study tests a new treatment called Radspherin® for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread in the abdomen. Participants receive a single injection of radioactive beads into the belly during surgery, alongside standard chemot…

This study tests a new experimental drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, pancreatic, skin cancer, or glioblastoma. The main goal is to check the drug's safety and find the right dose. About 80 adults will take part in two p…

This study tests a new treatment for several types of cancer that have a specific marker called CD70. Researchers take a patient's own white blood cells, modify their genes in the lab to help them recognize and attack CD70-positive cancer cells, and then return them to the patien…

This study tests whether adding a targeted drug (olaparib) to heated chemotherapy given during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III ovarian cancer will take olaparib pills before and after surgery. The goal is to find the best dose and …

This phase 3 trial tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian cancer live longer. About 520 participants who have already had some chemo will be randomly assigned to get surgery with or without this heated …

This study tests a new drug called HS-20089 against standard chemotherapy in people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatments. About 468 women will be randomly assigned to receive either HS-20089 or a doctor-ch…

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from growing back in people whose cancer had previously responded to platinum chemotherapy. About 528 adults with recurrent platinum-sensitive ovarian cancer will receive ei…

This early-phase study tests a new drug called BL-M07D1 in adults with advanced HER2-positive solid tumors (including breast, lung, stomach, and ovarian cancers) that have not responded to at least two prior treatments. The main goals are to check the drug's safety, find the best…

This study tests a new drug (LBL-024) combined with a standard chemotherapy (paclitaxel) in about 110 adults with ovarian cancer that has stopped responding to platinum-based treatments. The goal is to see if the combination can shrink tumors and delay cancer growth. Participants…

This study tests a new drug called XNW28012 in people with advanced solid tumors (like pancreatic, ovarian, or cervical cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 participants will take part in tw…

This study tests whether a combination of three drugs—weekly paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—can shrink tumors in adults whose ovarian cancer has returned. About 20 participants will receive the drugs and visit the clinic every two months for checkup…

This early-stage study tests a new personalized immunotherapy called Innocell for women with recurrent epithelial ovarian cancer. The treatment uses a patient's own tumor tissue to create a custom therapy. The main goals are to see if it is safe and if it can boost the immune sys…

This study tests an experimental drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tu…

This study tests whether a weekly chemotherapy schedule works better than the standard every-3-weeks schedule for people with advanced ovarian cancer that is not responding well to initial treatment. About 250 adults with stage III or IV ovarian cancer will be randomly assigned t…

This study tests if a new version of the drug olaparib (DWZ2501) works the same as the current version (DWC202510) in people with advanced ovarian cancer linked to a BRCA gene mutation. About 40 adults who are already stable on olaparib will take both versions at different times …

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better target and attack cancer cells. The main goals are to check…

This study looks at whether women with advanced ovarian cancer who have had all visible tumor removed can safely receive only 3 cycles of chemotherapy instead of the usual 6, followed by the maintenance drug niraparib. The goal is to see if the shorter chemo course is just as eff…

This study tests a new drug, SHR-A1811, combined with standard chemotherapy (carboplatin and bevacizumab) in people whose ovarian cancer has returned after initial treatment but still responds to platinum-based drugs. The goal is to find the safest dose and see how well the combi…

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This study tests a new drug called HLX43 in about 190 women with cervical or ovarian cancer that has come back or spread and did not respond to standard first treatment. The drug is designed to target and kill cancer cells. The goal is to see if it can shrink tumors and slow dise…

This early-phase study tests whether a new treatment using a patient's own modified immune cells (called CAR T cells) is safe for women with ovarian cancer that came back after standard platinum-based chemotherapy. The cells are designed to target a protein called B7-H3 found on …

This study is for people with ovarian or endometrial cancer that came back after initial treatment with platinum-based chemotherapy. It tests a new drug, sacituzumab govitecan, combined with cisplatin to find the safest dose and see if it can shrink tumors. About 54 participants …

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-stage study tests a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have measurab…

This early-stage study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find the safest dose and check for side effects. Participants have cancers like head and neck, lung, breast, or ovarian cancer that haven't r…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer getting worse. About 770 adults whose cancer responded to second-line chemothera…

This study tests whether adding a second drug (bevacizumab) to standard niraparib treatment helps keep advanced ovarian cancer from coming back longer. About 970 women with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer will take part. The main goal is to …

This early-stage study tests a new treatment called IVX037, a virus injected directly into tumors, for people with advanced colorectal, stomach, or ovarian cancers that have stopped responding to standard treatments. The study has two parts: first, testing IVX037 alone, then comb…

This study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The goal is to find a safe dose and see if it can shrink tumors. About 216 adults with tumors that have sp…

This program provides access to an experimental drug called AVM0703 for people with various solid tumors or blood cancers who have not responded to other treatments. It is available in the US upon a doctor's request. So far, 37 patients have received the drug, and side effects ha…

This early-stage trial tests a new drug called BI-1808, alone or with pembrolizumab, in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and infuse th…

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in 24 women whose ovarian cancer has returned after previous treatments. The main goals are to check safety and find the best dose, while also seeing if the combi…

This study tests a new two-drug combination for people with advanced ovarian cancer that has a specific protein called HER2. The drugs are distamab vedotin (a targeted therapy) and carboplatin (a standard chemo). The goal is to see if this combo works better and causes fewer side…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers (like breast, stomach, lung, or ovarian cancer) that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how long that effect last…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will receive the drug combination to see if it slows cancer growth. The goal is to find better options fo…

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…

This early-stage study tests a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back. The therapy uses a patient's own immune cells, modified to better attack cancer cells that have a protein called mesotheli…

This study tests whether a natural compound called isoquercetin can reduce blood markers linked to dangerous clots in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal is to see if the s…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study tests a new drug called INCB123667 against standard chemotherapy in people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The cancer must also have high levels of a protein called cyclin E1. About 466 participants will be r…

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab after initial chemotherapy for advanced ovarian cancer. About 900 participants will receive either the new treatment or standard care to see if it delays cancer growth. The…

This study is testing a new robotic surgery system (Medtronic Hugo™) for hysterectomy, a surgery to remove the uterus. It includes 70 adult patients with conditions like fibroids, endometriosis, or certain cancers. The goal is to see if the robot can perform the surgery safely an…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find a safe dose and check for side effects. About 319 participants will receive the drug to see…

This study looks at how well the drug T-DXd works for people with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. About 100 adults in the US will be followed to see if their tumors shrink or stop growing. The goal is to u…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests a new drug, INCB123667, in 160 people with a specific type of ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants must have a genetic marker called cyclin E1 overexpre…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has returned. TUB-040 is designed to deliver a cancer-killing agent directly to tumor cells that have a specific marker (N…

This study tests a technique called acute normovolemic hemodilution (ANH) during ovarian cancer surgery. ANH involves removing some blood before surgery and replacing it with fluids, then giving the blood back later. The goal is to see if this reduces the need for donor blood tra…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study tests an experimental drug called AZD5335, alone or with other cancer treatments, in people with advanced ovarian, lung, or endometrial cancer. The goal is to see if it is safe and can shrink tumors. About 506 participants will take part in this early-phase trial.

This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate tiny leftover cancer in people with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 30 participants will be randomly assigne…

This study tests a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in people with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive more chemotherapy plus two maintenance drugs (olapar…

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with platinum-resistant ovarian cancer live longer without their cancer growing. About 33 adults with this hard-to-treat cancer will receive the combination. The goal is t…

This early study tests a new treatment called SY001 for people with advanced ovarian or pancreatic cancer that has not responded to prior therapy. SY001 uses specially engineered immune cells (CAR-macrophages) to attack cancer cells that carry a protein called mesothelin. The mai…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This study is for people with high-grade ovarian cancer who still have small amounts of cancer (called minimal residual disease) after their first round of treatment. The trial will test whether adding a combination of three drugs—pembrolizumab, bevacizumab, and low-dose cyclopho…

This study tests two oral drugs, fuzuloparib and apatinib, given before surgery for people with advanced ovarian cancer that has a specific genetic marker (HRD-positive). The goal is to shrink tumors enough for complete removal and avoid chemotherapy. About 48 participants will r…

This study tests whether adding two drugs, hydroxychloroquine and nelfinavir, to standard maintenance therapy can help keep high-grade serous ovarian cancer from coming back. About 38 women whose cancer responded well to initial platinum chemotherapy will receive the drug combina…

This early-phase study tests a new drug, LNCB74, in about 145 people with advanced solid tumors (ovarian, breast, lung, and others). The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the best dose for futur…

This early-phase study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This early-phase study is testing whether adding aspirin to standard chemotherapy can help the immune system fight ovarian, fallopian tube, or peritoneal cancer more effectively. About 100 women will receive aspirin alongside their chemo before surgery. Researchers will measure c…

This early-stage trial tests a new drug called BL0175 in postmenopausal women with advanced hormone receptor-positive breast, ovarian, or endometrial cancer. The main goals are to check safety, find the best dose, and see if it helps shrink tumors. Only 9 participants will be enr…

This study tests a treatment for women whose mucinous ovarian cancer has come back. Doctors will perform surgery to remove visible cancer, then deliver heated chemotherapy directly into the abdomen. The goal is to see if this approach helps patients live longer without the cancer…

This study tests an investigational drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, primary peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the treatment can shrink tumors. About 612 participants…

This study tests a new drug combination (carboplatin and mirvetuximab) as the first treatment for people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific marker (folate receptor alpha). About 70 participants will receive the drugs before and after s…

This early-phase study tests a new drug, QXL138AM, for safety and tolerability in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. Participants must have tried standard treatments without success. The study will also look…

This study tests whether the drug belzutifan can shrink or slow the growth of clear cell cancers of the ovary, uterus, cervix, vagina, or vulva that have come back or not gone away. About 32 adults will receive belzutifan pills and be monitored for tumor response and side effects…

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Niraparib works by blocking cancer cells from repairing their DNA, which can slow or stop tumor growth. Researchers will also study how…

This study tests two different maintenance therapies for women with advanced ovarian cancer who have had complete surgery and chemotherapy. Participants will receive either niraparib alone or niraparib plus bevacizumab to see which better delays cancer return. The trial involves …

This study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…

This early-stage study tests a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to prior treatments. The main goals are to check if the drug is safe and to find the best dose. About 282 participants will take part i…

This study tests a new treatment called EBNK-001, which uses donor immune cells (natural killer cells) to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive these cells alon…

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer. About 500 newly diagnosed adults will receive either the drug combination or chemotherapy …

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…

This study tests a new drug called AZD8205, alone or with other cancer drugs, for people with advanced solid tumors like breast, ovarian, or lung cancer that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 460 adul…

This study tests a personalized cancer vaccine made from patients' own tumor cells. The goal is to train the immune system to fight metastatic cancers like melanoma, breast, lung, and colorectal cancer. Participants receive eight injections over 16 weeks. The study is for adults …

This study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…

This study tests a new drug called azenosertib against standard chemotherapy in people with ovarian cancer that no longer responds to platinum-based treatments. The trial includes 420 women whose tumors have a specific protein (cyclin E1). The goal is to see if azenosertib can sl…

This early-phase trial tests a new treatment using specially engineered natural killer (NK) cells that target a protein called TROP2 found on cancer cells. The cells are given directly into the abdomen to people with ovarian or pancreatic cancer that has stopped responding to sta…

This early-stage study tests an experimental drug called ABBV-901, alone or with a standard drug bevacizumab, in about 207 adults with ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug shrinks tumors. Participa…

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the …

This study tests whether adding mirvetuximab soravtansine to standard bevacizumab maintenance therapy can delay cancer return in women with a specific type of recurrent ovarian, fallopian tube, or peritoneal cancer. About 520 adults whose cancer has a high level of a protein call…

This study tests whether a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) can help keep advanced ovarian, fallopian-tube, or primary peritoneal cancer from coming back after initial treatment. About 120 adults with a specific genetic feature (HRD) will …

This study tests a new drug, trastuzumab deruxtecan (T-DXd), in people with recurrent ovarian cancer whose tumors have stopped responding to PARP inhibitors. T-DXd targets a protein called HER2 found on some cancer cells. The trial compares T-DXd to standard chemotherapy to see w…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This study looks at whether removing enlarged lymph nodes in the chest during surgery can help people with advanced ovarian cancer live longer without the cancer coming back. It involves 52 women with stage III or IV ovarian cancer whose chest lymph nodes are enlarged but small. …

This study is testing an experimental drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. About 272 people with cancers like ovarian, end…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This study tests whether using a special camera and fluorescent dye during surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after the operation. About 310 women with ovarian cancer who need bowel surgery will take part. The goal is to see if this…

This study tests different immunotherapy drug combinations in women with a type of ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see which combinations can shrink tumors or slow the cancer's growth. About 60 participants will join this phase 2 tr…

This study tests an experimental drug called COM701 in people with ovarian cancer that came back after treatment but still responds to platinum chemotherapy. The goal is to see if COM701, given as a maintenance therapy every three weeks, can delay cancer progression longer than a…

This study tests a new treatment for advanced ovarian cancer using a patient's own immune cells that are modified in the lab to better attack the cancer. About 100 adults with stage III or IV ovarian cancer that has come back after initial treatment will receive these modified ce…

This study is for people with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. It tests a new drug called AOH1996, which works by blocking certain enzymes that cancer cells need to grow. The main goals are to find the be…

This study compares a new method called PIPAC, which delivers chemotherapy as a spray directly into the abdomen, with standard chemotherapy for advanced ovarian cancer. The goal is to see if PIPAC can better shrink tumors before surgery. About 60 adults with high-grade serous ova…

This study is testing a new treatment that uses a radioactive substance to target and destroy cancer cells in people with advanced solid tumors (like pancreatic, stomach, or ovarian cancer) that have not responded to standard treatments. The therapy works by attaching to a protei…

This study looks at whether having surgery after chemotherapy helps people with recurrent ovarian cancer live longer without the cancer growing. It involves 80 participants who have already responded to chemo. The goal is to see if the surgery improves outcomes compared to chemo …

This early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This study tests whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills for as long as they work. The goal is to see if this approach can delay the c…

This study tests a special program called PROADAPT for women aged 70 and older (or 60+ with health issues) who have advanced ovarian cancer and need surgery. The program includes nutrition advice, physical exercises, and education before surgery, plus extra support during the hos…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy helps women with advanced HER2-expressing ovarian cancer live longer without their cancer growing. About 582 participants will receive either the combination or bevacizumab …

This study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer. About 44 participants will receive different doses to find the safest and most effective one. The goal is to control the disease and reduce tumors, n…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests a new drug called CUSP06 for people with ovarian cancer or other solid tumors that have stopped responding to standard treatments. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin directly. The main goals are t…

This study tests a drug called valemetostat in people with advanced solid tumors that have certain gene changes (like SMARCB1 or ARID1A). The drug aims to reactivate protective genes to slow or stop cancer growth. About 900 adults will take the drug daily for up to 2 years, with …

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This early-stage trial tests whether a new type of immune cell therapy is safe for people with ovarian cancer that has come back. The treatment uses a patient's own T cells, which are modified in a lab to recognize and attack cancer cells that have a specific marker (FSHR). Up to…

This study explores whether a tampon can collect samples to detect endometrial (uterine) and ovarian cancer early. Researchers will analyze DNA and proteins from tampons used by 1,500 women before surgery. The goal is to develop a simple, non-invasive test that could catch these …

This study is testing whether a new blood test can reliably detect ovarian cancer by looking at tiny particles called extracellular vesicles. Researchers will collect blood from 1,500 postmenopausal women aged 50-74 in Queensland, Australia, and check how handling and shipping af…

This study is testing a new type of PET scan that targets a protein called Trop2, found on many solid tumors. The goal is to see if this scan can find and stage cancers like bladder, lung, liver, and ovarian cancer better than current methods. About 400 adults with confirmed or s…

This study is testing whether combining a standard CA125 blood test with other blood markers can help detect ovarian cancer earlier in women at low risk. Researchers will track changes in these markers over time in 8,000 postmenopausal women aged 50-75 who have at least one ovary…

This study aims to create a test that can find endometrial, ovarian, and cervical cancers early using a sample of vaginal fluid or blood. Researchers will look for specific DNA markers and high-risk HPV in about 3,100 women. The goal is to make cancer detection easier and more ac…

This study looks at whether buying over-the-counter pain relievers or digestive aids can be an early warning sign for 10 types of cancer, including pancreatic, colon, and ovarian cancer. Researchers will compare the shopping habits of 2,900 people—some recently diagnosed with can…

This study is testing whether changes in platelet RNA can help doctors diagnose ovarian cancer more accurately and earlier. Researchers will collect blood samples from 245 women—some with ovarian cancer or an ovarian mass, and some healthy—to see if a new blood test works better …

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery. Surgeons can then see and remove tumors they might otherwise miss. About 170 women with suspected or recurrent ovarian cancer will take part, and the study lasts about 2 weeks per person.

This study is testing a new platform that uses advanced genetic and functional tests to better understand tumors from 300 people with various high-risk cancers, including leukemia, myeloma, and pancreatic cancer. The goal is to see if this detailed analysis can change the recomme…

This study is testing a new blood test that uses laser light and artificial intelligence to find signs of five different cancers (breast, colon, pancreatic, ovarian, and lung) at an early stage. Researchers will collect blood samples from 1,400 people aged 45 and older who are su…

This study is testing whether a computer model can predict if a woman carries a harmful BRCA gene mutation just by looking at ultrasound images of her healthy ovaries. Over 6,400 women will participate, and the goal is to create a simple, non-invasive screening tool. If successfu…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing whether yearly vaginal ultrasound can accurately detect ovarian cancer in women at intermediate to high risk, while reducing unnecessary false alarms. Researchers will screen 65,000 women from Kentucky over time and track how often the test correctly identif…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early and tell which type it is. In people with lung cancer, the test will also check for any cancer…

This study is testing a new type of PET/CT scan that uses a special tracer called 18F-T2 to find cancers that have high levels of a protein called CAIX. About 200 adults with cancers like kidney, bladder, lung, or breast cancer will get this scan to see if it works better than th…

This study tests whether drinking tart cherry juice can prevent nerve damage (neuropathy) caused by the chemotherapy drug paclitaxel in people with breast or ovarian cancer. About 86 participants will be randomly assigned to take either a high or low dose of the juice during thei…

This study looks at whether different types of preventive surgery can lower the chance of getting ovarian cancer in women who have a high genetic risk. About 480 women with certain gene changes (like BRCA1/2) will choose either standard surgery, delayed ovary removal, or close mo…

This study looks at a new approach to prevent ovarian cancer in women with BRCA or other high-risk gene mutations. Instead of removing both ovaries and fallopian tubes at once, participants first have only the fallopian tubes removed, delaying ovary removal until later. The goal …

This study looks at whether removing the fallopian tubes first and delaying ovary removal is a safe way to prevent ovarian cancer in women with BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1 gene mutations. About 3,000 women will take part. The goal is to see if this two-step approach wo…

This study tests whether a program of physical activity, nutritional advice, and psychological support before surgery can improve recovery and quality of life in patients with ovarian or endometrial cancer. 64 participants will be randomly assigned to either receive standard care…

This study tests whether a virtual mind-body program called IM@Home can reduce fatigue and improve quality of life for adults with head and neck, thoracic, gynecologic, or other cancers who are receiving treatments like chemotherapy or radiation. About 480 participants will be en…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce diarrhea and colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for side ef…

This study tests whether a 16-week virtual exercise program can help patients with ovarian or endometrial cancer maintain leg strength and reduce numbness or tingling caused by chemotherapy. About 30 adults who have had surgery and are starting chemo will participate. The goal is…

This study tests whether a combination of two drugs (propranolol and etodolac) plus mind-body training and music therapy can reduce stress in women with advanced ovarian cancer undergoing surgery. About 35 participants will be randomly assigned to receive this bundle or standard …

This study looks at whether a program of exercise and nutrition (called prehabilitation) can help people aged 65 and older with advanced ovarian or pancreatic cancer get ready for surgery while they receive chemotherapy. The main goal is to see if participants can stick with the …

This study tests a yoga-based lifestyle program for women with ovarian cancer who are about to receive chemotherapy and surgery. The goal is to see if the program is practical and helps improve quality of life. Researchers will enroll 40 women at MD Anderson Cancer Center.

This study tests a telehealth program called REVITALIZE to see if it can lessen how much fatigue interferes with daily life for people with advanced ovarian cancer who are taking PARP inhibitors. About 240 adults will be randomly assigned to either the REVITALIZE program or recei…

This study tests a new communication tool called CASI for people with advanced ovarian cancer, their caregivers, and doctors. The goal is to see if using this tool helps patients and doctors better discuss what matters most during appointments. About 112 participants will be enro…

This study tests whether the drug riluzole can prevent memory and thinking problems (often called 'chemo brain') in people receiving chemotherapy for various cancers. About 24 adults with breast, lung, or other cancers will receive either riluzole or a placebo during their chemo.…

This early-phase study tests whether a single dose of psilocybin, given with therapy, can reduce the intense fear of cancer returning in women who have completed treatment for early-stage breast or ovarian cancer and are now in remission. Twenty participants will receive preparat…

This study tests a short counseling program called CALM for women with advanced ovarian cancer. The goal is to see if it's practical and helpful for reducing stress and improving well-being. Participants will fill out questionnaires and may receive up to 6 therapy sessions.

This study looks at how ovarian cancer affects the immune system, especially in the bone marrow and blood. Researchers will compare immune cells from 90 women with ovarian cancer to those without cancer. The goal is to find ways to retrain immune cells to better attack the tumor,…

This study looks at whether preserving the left colic artery during surgery for colon, rectal, or ovarian cancer helps keep the remaining colon well-supplied with blood. About 50 adults scheduled for surgery will have their colon's blood flow measured with and without the artery …

This study looks at whether a digital app can help cancer patients get genetic testing directly from their oncologist, instead of visiting a separate genetics clinic. The goal is to see if this approach reduces patient distress and improves care. About 180 adults with breast, pro…

This study is for adults with cancers that have spread to the lining of the abdomen. Doctors will remove most tumors during surgery, then give heated chemotherapy directly into the abdomen. They will also test the same chemo on tumor samples in the lab to see if lab results match…

This early-phase study is testing a new substance called RAD301 to see how it moves through the body and how much radiation it gives off. It involves 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to measure sa…

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer. Researchers will use these samples to develop and improve tests that detect cancer DNA in the blood, which may help monitor for cancer return or how well treatment is working. …

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study looks at the bacteria and natural chemicals in the vagina to find new ways to detect ovarian cancer early. Researchers will collect vaginal swabs and stool samples from 50 healthy volunteers (people with ovaries but no known cancer or genetic risk). These samples will …

This study looks at how ovarian cancer is currently treated in Brazil. Researchers will collect information from 250 patients to find what works well and what could be improved. The goal is to help set new quality standards for ovarian cancer care across the country.

This study looks at whether a family history screening program can help more women in rural Georgia get tested for BRCA gene mutations linked to breast and ovarian cancer. About 3,200 women from public health clinics will take part. The goal is to see if the program increases the…

This study looks at whether a polygenic risk score (PRS) can help predict the chance of developing ovarian cancer. Researchers will compare the genetic scores of 1300 Italian women—some with ovarian cancer and some without. Participants will give a blood sample and fill out a que…

This study is developing a blood test that uses artificial intelligence to spot cancer early and see how well treatments are working. Researchers will analyze blood samples from 6000 adults with or without cancer to find unique signals in platelets and immune cells. The goal is a…

This study looks at how 3-4 cycles of chemotherapy before surgery affects frailty in adults over 55 with advanced ovarian or endometrial cancer. Researchers will use an electronic frailty index to measure changes in fitness and cognitive function. The goal is to understand whethe…

This study is for people with advanced ovarian cancer whose disease has stopped responding to platinum-based chemotherapy. Researchers will collect a sample of your archived tumor tissue to test whether a special method (called DRP) can predict if you are likely to benefit from c…

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study looks at how the antifungal drug itraconazole changes the way the body processes a cancer drug called AZ14170132, which is part of a targeted therapy for ovarian, peritoneal, and fallopian tube cancers. About 24 people with these cancers will take both drugs in a fixed…

This study looks at immune cells (T cells) in tumor samples from 1,100 people with cancers like head and neck, ovarian, cervical, lung, and brain cancer. Researchers want to understand how these cells behave, especially a protein called PD-1. No new treatments are tested—only sam…

This study aims to understand how chemotherapy given before surgery for advanced ovarian cancer affects thinking skills like memory and attention. Researchers will enroll 18 adults recently diagnosed with ovarian cancer who are scheduled to receive standard chemo drugs (carboplat…

This study collects blood and tumor samples from up to 3,300 people with a high genetic risk for breast, ovarian, or related cancers. Researchers aim to understand how these cancers develop and how treatments work. Participants include those with BRCA1/2 or other gene mutations, …

This study is building a detailed genetic database of ovarian cancer in Taiwan. Researchers will analyze tumor tissue from 300 patients to find gene changes linked to treatment resistance and survival. The goal is to pave the way for more personalized therapies in the future, but…

This study aims to understand why some ovarian cancer patients respond well to platinum-based chemotherapy for years, while others do not respond at all. Researchers will compare the genetics, biology, and medical history of 55 patients from two groups: those whose cancer worsene…

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer. The samples will be stored and used in future research to better understand how cancers grow and respond to treatment. No new treatments are being tested; the goal…

This study looks at 50 people with ovarian cancer that came back quickly after treatment. Researchers will track their health and survival to learn more about who benefits from further therapies. The goal is to improve how doctors classify and care for these patients.

This study is looking for genetic targets in ovarian cancer, especially a common and aggressive type called high-grade serous ovarian carcinoma. Researchers will use computer models, lab tests on tissue samples, and experiments on cancer cells to understand how certain genes and …

This early study is testing a small implantable device that sits inside a tumor and measures how different chemotherapy drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will have the device placed and removed during standard…

This study is a large registry that will follow about 2,000 people in Germany with advanced ovarian or endometrial cancer. Researchers will collect information on treatments, side effects, and quality of life over time. The goal is to understand what really happens in everyday me…

This study tests whether an artificial intelligence system can help doctors better manage blood pressure and fluid levels during complex ovarian cancer surgery. The approach aims to reduce complications like kidney injury and fluid buildup in the lungs. About 52 adults scheduled …

This study is collecting tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new markers that link tumor genetics and immune response to how the disease behaves. Participa…

This study looks at 88 women with advanced ovarian cancer to compare two tests that check for DNA repair problems (HRD status). The goal is to see if the test results match how well the cancer responds to standard platinum chemotherapy. If a test shows a repair problem, a PARP in…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …

This study is building a platform to better predict who is at risk for developing or having a recurrence of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will analyze participants' blood and genetic information to find markers that coul…

This study will collect genetic information and health records from 25,000 people who have cancer or are at risk for it. The goal is to learn more about what drives cancer and how to better tailor treatments. Participants will not receive a new therapy, but their data may help fu…

This study follows 1,000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Participants receive usual care, and researchers collect data on surge…

This study collects blood or cheek swab samples from people with cancer who are being treated at the National Cancer Institute. Researchers want to learn how genetic differences may affect how the body processes cancer treatments and whether certain genes are linked to side effec…

This study aims to create a simple, Spanish-language tool to help ovarian cancer patients decide on their maintenance therapy. Researchers will work with 70 Spanish-speaking patients and their doctors to test the tool. The goal is to make sure patients feel confident and informed…

This study is for people with advanced cancers who are taking targeted treatments for months or years. Researchers will interview 75 participants to understand their experiences and needs. The goal is to find better ways to support patients living with chronic cancer treatments.

This study looks at whether freezing ovarian tissue can help preserve fertility in people with disorders of sex development who are at high risk of infertility or cancer. Up to 50 participants under 30 will have their tissue frozen before their ovaries are removed. The goal is to…

This study aims to see if watching a video before genetic testing helps people with certain cancers better understand their hereditary cancer risk. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Resear…

This study aims to create and improve educational materials about genetic testing for people with breast, ovarian, prostate, pancreatic, or colorectal cancer. Researchers will interview 445 participants from diverse cultural and language backgrounds to get their feedback on the m…

This study takes tumor samples from people with breast, colorectal, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to find personalized treatment options and lear…

This study aims to gather information from cancer patients (breast, lung, ovarian, multiple myeloma, or AML) who use a remote symptom monitoring system during their routine treatment. Participants will complete weekly surveys about their symptoms for at least 12 weeks. The goal i…

This study looks at whether a blood test can find changes in the BRCA gene that might signal ovarian cancer is coming back earlier than usual scans. About 130 women with BRCA-mutated ovarian cancer who are starting maintenance therapy with a PARP inhibitor will give blood samples…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can detect ovarian cancer coming back earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time after their initial tr…

This study looks at how women aged 70 and older with advanced ovarian cancer handle a type of drug called PARP inhibitors. These drugs can cause side effects like low blood counts, which may be more common in older patients. The goal is to find out which factors affect how much o…

This study is observing 750 women with advanced ovarian cancer in Germany to gather real-world information about their treatment journey, including chemotherapy and maintenance therapy. Researchers want to understand how BRCA testing affects treatment choices and what patients ex…

This study aims to identify women at risk for hereditary breast, ovarian, and colorectal cancers by offering genetic screening and counseling at mobile mammography units. About 1,000 underserved women in Texas will be invited to participate when they come for their routine mammog…

This study aims to find biological markers in tumor, blood, and other samples from 350 ovarian cancer patients. Researchers will track how these markers change with treatment and relate to outcomes like progression-free survival. The goal is to better understand why some cancers …